SCHEMBL6531325

SCHEMBL6531325

C[Si](C)(C)CCOCn1ccnc1I

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9638271 0.83 DGAT1 (0.41) DGAT1
SCHEMBL1488779 0.81 KMT2A (0.43) DGAT1
SCHEMBL20028555 0.81
Hydrochloric Acid SCHEMBL15455783 0.80 DGAT1 (0.37) DGAT1
SCHEMBL17810435 0.80 DGAT1 (0.37) DGAT1
SCHEMBL1126106 0.80 TLR8 (0.47) DGAT1
SCHEMBL3574886 0.80 DGAT1 (0.42) DGAT1
SCHEMBL2153326 0.79 DGAT1 (0.40) DGAT1
SCHEMBL2061624 0.79 ALDH1A1 (0.35)
SCHEMBL22409097 0.79 DGAT1 (0.36) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 US disclosed
WO-2025125666-A1 SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 WO disclosed
US-20250171439-A1 INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2025-05-29 US disclosed
EP-4463462-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2024-11-20 EP disclosed
CN-118715231-A Complement factor inhibitors and uses thereof 安尼艾克松股份有限公司 2024-09-27 CN disclosed
US-20230391778-A1 INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-12-07 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed
EP-2033952-A1 Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity Shionogi&Co., Ltd. (JP) 2009-03-11 EP disclosed
US-20080261985-A1 SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) TRUSTEES OF DARTMOUTH COLLEGE 2008-10-23 US disclosed
US-20080261985-A1 SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) TRUSTEES OF DARTMOUTH COLLEGE 2008-10-23 US disclosed
US-20080233195-A1 SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH TRUSTEES OF DARTMOUTH COLLEGE (US) 2008-09-25 US disclosed
US-20080233195-A1 SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH TRUSTEES OF DARTMOUTH COLLEGE (US) 2008-09-25 US disclosed
WO-2008064133-A9 SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) DARTMOUTH COLLEGE (US) 2008-07-31 WO disclosed
WO-2008064133-A1 SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) TRUSTEES OF DARTMOUTH COLLEGE (US) 2008-05-29 WO disclosed
WO-2008064132-A2 SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH TRUSTEES OF DARTMOUTH COLLEGE (US) 2008-05-29 WO disclosed
WO-2005014588-A1 SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY ARGENTA DISCOVERY LIMITED (GB) 2005-02-17 WO disclosed
CN-1489580-A Imidazole derivatives - 2004-04-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261985-A1 SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) HMOX1, MCL1, HMOX2 DGAT1 4364/4885
US-20230391778-A1 INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES GRIN2B, HTR2B, HTR1A DGAT1 3649/4885
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DGAT1 2858/4885
US-20250171439-A1 INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES GRIN2B, HTR2B, HTR1A DGAT1 3649/4885
US-20080233195-A1 SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH BMP4, BMP2, BMP1 DGAT1 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.